(secondQuint)Phase I/II Study of Curdlan Sulfate.

 In Phase I of the study, escalating single doses of intravenous curdlan sulfate are tested.

 In Phase II, curdlan sulfate is administered daily for 7 days.

 (NOTE: Phase I is completed.

).

 Phase I/II Study of Curdlan Sulfate@highlight

To assess the safety and tolerance of curdlan sulfate, as well as its anti-HIV activity, in HIV-infected patients with CD4 T-lymphocytes less than 500 cells/mm3, using first single doses and then, after FDA review, daily doses for 7 days.

